IP Library › Granted Patent US 12,674,155
Granted Patent B2
US 12,674,155 · App. 17/288,435 · Granted Jul 7, 2026

Targeted chondroitinase ABC fusion proteins and complexes thereof

Inventors: Gregory Allan Hudalla (Gainesville, FL); Benjamin G. Keselowsky (Gainesville, FL); Dillon T. Seroski (Gainesville, FL); Shaheen A. Farhadi (Gainesville, FL); Christine E. Schmidt (Gainesville, FL); Nikunj Kumar Agrawal (Gainesville, FL)
Assignee: University of Florida Research Foundation, Incorporated
C12N9/88C12N9/16C12Y304/24035C12Y402/02004C12Y402/0202C12Y402/02021
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,674,155
App. No.
17/288,435
Granted
Jul 7, 2026
Kind
B2
Abstract

Described herein are targeted ChABC fusion proteins, complexes thereof, and uses thereof. The targeted ChABC fusion proteins can include a ChABC polypeptide that can be linked to a Gal-3 polypeptide. Monomer targeted ChABC fusion proteins can form homogeneous or heterogeneous complexes. The targeted ChABC fusion proteins and complexes thereof can be formulated as pharmaceutical formulations. The targeted ChABC fusion proteins, complexes thereof, and formulations thereof can be administered to a subject in need thereof.

Claims (19)

1 . A targeted effector fusion protein comprising a polypeptide sequence that is identical to any one of SEQ ID NOs: 15-16.

2 . A multimeric targeted effector fusion protein complex comprising:

at least two targeted effector fusion proteins, wherein each of the at least two targeted effector proteins is according to claim 1 , and the at least two targeted effector proteins are conjugated to each other by binding between an alpha coil polypeptide or a random coil polypeptide in each of the at least two targeted effector proteins.

3 . The multimeric targeted effector fusion protein complex of claim 2 , wherein the multimeric targeted effector fusion protein complex is homogeneous.

4 . The multimeric targeted effector fusion protein complex of claim 2 , wherein the multimeric targeted effector fusion protein complex is heterogeneous.

5 . A polynucleotide that encodes the targeted effector fusion protein of claim 1 .

6 . The polynucleotide of claim 5 , wherein the polynucleotide sequence is SEQ ID NO: 6 or 7.

7 . A vector comprising:

a polynucleotide according to claim 5 .

8 . A single fusion polypeptide sequence comprising:

at least two targeted effector fusion proteins as in claim 1 , wherein each of the at least two targeted effector fusion proteins are directly fused at the C-terminus, N-terminus, or both the C-terminus and N-terminus of at least one other targeted effector fusion protein of the at least two targeted effector fusion proteins.

9 . A single fusion polypeptide sequence comprising:

at least two targeted effector fusion proteins as in claim 1 , wherein each of the at least two targeted effector fusion proteins are operatively linked at the C-terminus, N-terminus, or both the C-terminus and N-terminus to at least one other targeted effector fusion protein of the at least two targeted effector fusion proteins via one or more additional amino acids.

10 . A polynucleotide encoding the single fusion polypeptide of claim 8 .

11 . A vector comprising:

the polynucleotide according to claim 10 .

12 . A pharmaceutical formulation comprising:

one or more targeted effector fusion proteins as in claim 1 ; and

a pharmaceutically acceptable carrier.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 5, 2023
From: UNIVERSITY OF FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065774/0039 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2021
From: HUDALLA, GREGORY ALLAN; KESELOWSKY, BENJAMIN G.; SEROSKI, DILLON T.; FARHADI, SHAHEEN A.; SCHMIDT, CHRISTINE E.; AGRAWAL, NIKUNJ KUMAR
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Reel/Frame 057029/0200 →
Continuity (2)
Provisional Application 62751146 · Oct 26, 2018
Related Publication 20220106580A1 · Apr 7, 2022
References Cited (66)
US 11407797B2 · Hudalla et al. · 2022 [cited by applicant]
US 11603394B2 · Hudalla · 2023 [cited by examiner]
US 20050074865A1 · Afeyan et al. · 2005 [cited by applicant]
US 20050220792A1 · Agou et al. · 2005 [cited by applicant]
US 20050260222A1 · Gupta et al. · 2005 [cited by applicant]
US 20070098701A1 · Okano et al. · 2007 [cited by applicant]
US 20080234177A1 · Bremer et al. · 2008 [cited by applicant]
US 20110294983A1 · Desmet et al. · 2011 [cited by applicant]
US 20110318372A1 · Andersen et al. · 2011 [cited by applicant]
US 20140187487A1 · Shoichet et al. · 2014 [cited by applicant]
US 20170335311A1 · Gruskin · 2017 [cited by examiner]
US 20180073007A9 · Gruskin et al. · 2018 [cited by applicant]
US 20190218264A1 · Hudalla et al. · 2019 [cited by applicant]
US 20200262882A1 · Hudalla et al. · 2020 [cited by applicant]
US 20220098258A1 · Hudalla et al. · 2022 [cited by applicant]
EP 1748050 · 2007 [cited by applicant]
JP 2005537032A · 2005 [cited by applicant]
JP 2009515520A · 2009 [cited by applicant]
JP 2011520783A · 2011 [cited by applicant]
JP 2012514616A · 2012 [cited by applicant]
JP 2015528514A · 2015 [cited by applicant]
JP 2016040260A · 2016 [cited by applicant]
WO 1999012041A1 · 1999 [cited by applicant]
WO 2003090780A1 · 2003 [cited by applicant]
WO 2004019878A2 · 2004 [cited by applicant]
WO 2007058776A2 · 2007 [cited by applicant]
WO 2009143843A1 · 2009 [cited by applicant]
WO 2010078966A1 · 2010 [cited by applicant]
WO 2011034605A2 · 2011 [cited by applicant]
WO 2014089267A1 · 2014 [cited by applicant]
WO 2016127100A1 · 2016 [cited by applicant]
WO 2016172319A1 · 2016 [cited by applicant]
WO WO2018067660A1 · 2018 [cited by examiner]
Friedberg, Brief. Bioinformatics (2006) 7: 225-242 (Year: 2006). [cited by examiner]
Thorton et al. Nature structural biology, structural genomics supplement, Nov. 2000, pp. 991-994 (Year: 2000). [cited by examiner]
Chen et al. International Journal of Biological Macromolecules 72 (2015) 6-10 (Year: 2015). [cited by examiner]
Pakulska et al. Journal of Controlled Release 171 (2013) 11-16 (Year: 2013). [cited by examiner]
Barnes et al. Investigative Ophthalmology & Visual Science Jun. 2013, vol. 54, 1090 (Year: 2013). [cited by examiner]
Lee et al., Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2. Exp Mol Med. Nov. 14, 2014;46(11):e121. doi: 10.1038/emm.2014.69. [cited by applicant]
Extended European Search Report for Application No. EP 17859087.3, mailed Apr. 8, 2020. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2017/055076, mailed Feb. 21, 2018. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2017/055076, mailed Apr. 18, 2019. [cited by applicant]
International Search Report and Written Opinion mailed Jan. 4, 2019 for Application No. PCT/US2018/055213. [cited by applicant]
International Preliminary Report on Patentability mailed Apr. 23, 2020 for Application No. PCT/US2018/055213. [cited by applicant]
Invitation to Pay Additional Fees for Application No. PCT/US2020/020532, mailed May 21, 2020. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2020/020532, mailed Jul. 24, 2020. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2020/020532, mailed Sep. 10, 2021. [cited by applicant]
[No Author Listed], Plasmid Files. SnapGene. Retrieved from www.snapgene.com/resources/plasmid-files/?set=pgex_vectors_(ge_healthcare)&plasmid=pGEX-4T-1. Accessed on Nov. 4, 2021. 5 pages. [cited by applicant]
Brooks et al., Immunomodulatory Factors Galectin-9 and Interferon-Gamma Synergize to Induce Expression of Rate-Limiting Enzymes of the Kynurenine Pathway in the Mouse Hippocampus. Front Immunol. Oct. 17, 2016;7:422. doi… [cited by applicant]
Fettis et al., Engineering Reactive Oxygen Species-Resistant Galectin-1 Dimers with Enhanced Lectin Activity. Bioconjug Chem. Jul. 18, 2018;29(7):2489-2496. doi: 10.1021/acs.bioconjchem.8b00425. Epub Jul. 3, 2018. [cited by applicant]
Iken et al., Indoleamine 2,3-dioxygenase and metabolites protect murine lung allografts and impair the calcium mobilization of T cells. Am J Respir Cell Mol Biol. Oct. 2012;47(4):405-16. doi: 10.1165/rcmb.2011-0438OC. E… [cited by applicant]
Inohara et al., Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. Biochem Biophys Res Commun. Nov. 21, 2008;376(3):605-10. doi: 10.1016/j.bbrc.2008.09.041. Epub Sep. 20, 2008. [cited by applicant]
Krylov et al., Leucine Zipper. Encyclopedia of Life Sciences. 2001. 7 pages. [cited by applicant]
Li et al., Rate enhancement of an interfacial biochemical reaction through localization of substrate and enzyme by an adaptor domain. J Phys Chem B. Nov. 25, 2010;114(46):15113-8. doi: 10.1021/jp102820e. Epub Nov. 3, 20… [cited by applicant]
Litowski et al., Designing heterodimeric two-stranded alpha-helical coiled-coils. J Biol Chem. Oct. 4, 2002;277(40):37272-9. [cited by applicant]
Littlejohn et al., Expression and purification of recombinant human indoleamine 2, 3-dioxygenase. Protein Expr Purif. Jun. 2000;19(1):22-9. doi: 10.1006/prep.2000.1214. [cited by applicant]
Liu et al., Expression of immune checkpoint molecules in endometrial carcinoma. Exp. Ther Med. 2015;10(5):1947-52. [cited by applicant]
Liu et al., Galectins as modulators of tumor progression. Nat. Rev. Cancer. 2005;5(1):29-41. [cited by applicant]
Nishi et al., Functional and structural bases of a cysteine-less mutant as a long-lasting substitute for galectin-1. Glycobiology. Dec. 2008;18(12):1065-73. doi: 10.1093/glycob/cwn089. Epub Sep. 16, 2008. [cited by applicant]
Pechar et al., Coiled coil peptides and polymer-peptide conjugates: synthesis, self-assembly, characterization and potential in drug delivery systems. Biomacromolecules. Jul. 14, 2014;15(7):2590-9. doi: 10.1021/bm500436… [cited by applicant]
Weidle, et al. Fully Human Targeted Cytotoxic Fusion Proteins: New Anticancer Agents on the Horizon. Cancer Genomics Proteomics. 2012;9:119-33. [cited by applicant]
Weisel et al., Fibrin Formation, Structure and Properties. Subcell Biochem. 2017;82:405-456. doi: 10.1007/978-3-319-49674-0_13. Author Manuscript, 52 pages. [cited by applicant]
Wheeldon et al., Substrate channeling as an approach to cascade reactions. Nat Chem. Apr. 8, 2016:4;299-309. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2019/058230, mailed Feb. 5, 2020. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2019/058230, mailed May 6, 2021. [cited by applicant]
Dang, Molecular Approaches to Protein Dimerization: Opportunities for Supramolecular Chemistry. Front Chem. Feb. 8, 2022;10:829312. doi: 10.3389/fchem.2022.829312. [cited by applicant]